CD163 and diabetes mellitus: The decrease in sCD163 after RYGB was overall more pronounced and consistent in patients with diabetes compared with subjects with NGT (p = 0.08), but the concentrations of sCD163 in the two groups were similar after 12 months of follow‐up (Table 1, Figure 1a).